Camel Whey Protein Gel for the Treatment of Aphthous Ulcer

Sponsor
Kafrelsheikh University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04886011
Collaborator
(none)
20
2
2
3.5
10
2.8

Study Details

Study Description

Brief Summary

Higher prevalence of recurrent aphthous ulcer in young adults and the severity decreased with increasing age. The etiology of aphthous ulcer remains unclear. Other possible factors include trauma, drug use, deficiency in vitamin B12, folic acid, iron, stress, hormonal changes and metabolic diseases. Many topical agents such as local and systemic an- tibiotics, local antiseptics, topical NSAIDs, and topical corticosteroids are generally prescribed for symptomatic relief. Several approved drug for- mulations such as pills, mouthwash, sprays and paste such as vitamin B12, chlorhexidine mouthwash, steroid lozenges and local anesthetics are primarily suggested for the treatment of aphthous ulcer.

Camel whey protein gel was fabricated to get benefits of its antiinflammatory, immunomodulator, Antibacterial and antioxidant effects.

Condition or Disease Intervention/Treatment Phase
  • Combination Product: placebo gel
  • Combination Product: camel whey protein gel
N/A

Detailed Description

40 cases of recurrent aphthous ulcer patients as the research object,were randomly divide into the study group and the control group, each with 20 cases of both sexes with age ranging from 18 years to 50 years.

Inclusion criteria consisted of the following: (a) clinical examination and confirmed history of recurrent oral ulcer, (b) recurrence of the oral ulceration, and (c) patients in good condition with no serious systemic disease. Eligible persons were excluded if they were administered antibiotics or glucocorticoids or accepted periodontal or dental treat- ments that interfered with the results of our experimental drugs.

the control group will be subjected to placebo gel consisting of methyl cellulose gel whereas the study group will use camel whey protein dissolved in methyl cellulose gel base. the gel will be applied 1 day after ulcer appearance and will be stopped after ulcer disappearance

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Methylcellulose gelMethylcellulose gel
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Evaluation of Novel Topical Camel Whey Protein Gel for the Treatment of Recurrent Aphthous Stomatitis: Randomised Clinical Study
Actual Study Start Date :
May 15, 2021
Anticipated Primary Completion Date :
Aug 15, 2021
Anticipated Study Completion Date :
Aug 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: placebo gel

Methylcellulose gel was applied to the ulcer till complete healing

Combination Product: placebo gel
just methyl cellulose gel was applied to the ulcer

Experimental: camel whey protein gel

camel whey protein dissolved in methycellulose gel was applied to the ulcer till complete healing

Combination Product: camel whey protein gel
camel whey protein gel was prepared and dissolved in methyl cellulose gel base and applied to the ulcer

Outcome Measures

Primary Outcome Measures

  1. pain level [1 week]

    visual analog scale to measure pain level from 0 to 10. 0 means no pain at all and 10 means the most sever pain

  2. ulcer duration [10 days]

    time extended from ulcer presence till disseverance

Secondary Outcome Measures

  1. immunological analysis [10 days]

    the values of serum TNF-α, Il1, IL6 were measured before and after gel application using flow cytometry

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • clinical examination and confirmed history of recurrent oral ulcer,

  • recurrence of the oral ulceration

  • patients in good condition with no serious systemic disease.

Exclusion Criteria:
  • if they were administered antibiotics or glucocorticoids

  • accepted periodontal or dental treat-ments that interfered with the results of our experimental drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 oral medicine and periodontology outpatient clinic, faculty of dentistry, kafrelsheikh University Kafr Ash Shaykh Kafrelsheikh Egypt 214312
2 Walid Elamrousy Kafr Ash Shaykh Egypt 21614

Sponsors and Collaborators

  • Kafrelsheikh University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Walid Elamrousy, Principle investivagor and lecturer of oral medicine and periodontology, faculty of dentistry, kafrelsheikh university, Kafrelsheikh University
ClinicalTrials.gov Identifier:
NCT04886011
Other Study ID Numbers:
  • KFSAPH2021
First Posted:
May 13, 2021
Last Update Posted:
Jul 27, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 27, 2021